SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com

SCYNEXIS (NASDAQ:SCYX) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday.

SCYNEXIS Price Performance

Shares of NASDAQ SCYX opened at $1.04 on Friday. The stock has a market capitalization of $40.54 million, a P/E ratio of -1.41 and a beta of 1.67. SCYNEXIS has a 1-year low of $0.82 and a 1-year high of $3.07. The business has a fifty day moving average price of $1.06 and a 200 day moving average price of $1.24.

SCYNEXIS (NASDAQ:SCYX) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The firm had revenue of $0.98 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SCYX. Northern Trust Corp increased its position in SCYNEXIS by 51.9% during the 4th quarter. Northern Trust Corp now owns 153,518 shares of the company’s stock valued at $186,000 after buying an additional 52,466 shares in the last quarter. Squarepoint Ops LLC acquired a new position in SCYNEXIS during the 4th quarter valued at about $53,000. JPMorgan Chase & Co. acquired a new position in SCYNEXIS during the 4th quarter valued at about $49,000. Geode Capital Management LLC grew its holdings in shares of SCYNEXIS by 10.0% during the third quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock valued at $594,000 after buying an additional 36,405 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of SCYNEXIS by 22.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 195,393 shares of the company’s stock valued at $236,000 after buying an additional 35,233 shares during the last quarter. 54.37% of the stock is owned by institutional investors and hedge funds.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.